UNC Lineberger Comprehensive Cancer Center

First Citizens Bank Launches 2023 Teen Cancer America Campaign

Retrieved on: 
수요일, 11월 1, 2023
Adolescence, First Citizens Bank of South Carolina, Social media, UNC Lineberger Comprehensive Cancer Center, Ward, TCA, First Citizens BancShares, AYA, Research, Citizenship, National Cancer Institute, Quality of life, University of North Carolina at Charlotte, Duke Cancer Institute, Credit card, Internet, Hospital, Young adult, Atrium Health Wake Forest Baptist, University, Vanderbilt, Cancer, Patient, Birth control, Nursing, Pharmaceutical industry

RALEIGH, N.C., Nov. 1, 2023 /PRNewswire/ -- What if you could help a young person with cancer?

Key Points: 
  • That's the message behind First Citizens Bank's 2023 campaign to raise awareness and money for nonprofit Teen Cancer America (TCA), which develops specialized programs and facilities for teens and young adults with cancer.
  • First Citizens is encouraging everyone to donate to the nonprofit this fall and throughout the holiday season.
  • "By supporting Teen Cancer America, we can make a tremendous difference in the lives of the 90,000 young people diagnosed with cancer each year," said Jeff Ward, First Citizens' chief strategy officer and TCA national board member.
  • First Citizens and TCA recently helped dedicate a new infusion clinic at the N.C. Basnight Cancer Hospital at the University of North Carolina's Lineberger Comprehensive Cancer Center in Chapel Hill, N.C.

Tempus Announces Dr. Ned Sharpless as a Senior Strategic Advisor

Retrieved on: 
수요일, 5월 10, 2023
Technology, Clinical Trials, Health Technology, Software, Biotechnology, General Health, Pharmaceutical, Health, Oncology, Artificial Intelligence, UNC School of Medicine, University, Therapy, UNC, UNC Lineberger Comprehensive Cancer Center, Physician, Health equity, American Association of Physician Specialists, Cancer, Intelligence, Innovation, Research, University of North Carolina at Chapel Hill, Bangladesh Technical Education Board, Dana–Farber Cancer Institute, Harvard Medical School, National Cancer Institute, National academy, National Academy of Medicine, MD, School, Hospital, FDA, Massachusetts General Hospital, NCI, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Tempus, Medicine

Tempus, a leader in artificial intelligence and precision medicine, today announced that Norman E. “Ned” Sharpless, MD, will serve as a senior strategic advisor to Tempus and its leadership team, leveraging his vast experience as a medical policy expert and cancer researcher to further the company’s mission of improving patient outcomes.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced that Norman E. “Ned” Sharpless, MD, will serve as a senior strategic advisor to Tempus and its leadership team, leveraging his vast experience as a medical policy expert and cancer researcher to further the company’s mission of improving patient outcomes.
  • Dr. Sharpless was most recently the Director of the National Cancer Institute (NCI), part of the National Institutes of Health, a position he held from 2017 to 2022.
  • At the NCI, Dr. Sharpless was instrumental in championing health equity and modernizing clinical trials, among many other accomplishments.
  • Sharpless has had an indelible impact on the medical community in addressing major public health challenges and spurring innovation,” said Eric Lefkofsky, Founder and CEO of Tempus.

PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer

Retrieved on: 
목요일, 12월 15, 2022
Section, Neoplasm, Fast Track, Partnership, Merck & Co., Lead, Neck, MD Anderson Cancer Center, CPI, Biotechnology, Sharp, Research, Cervical cancer, COVID-19, Head, University, Clinical trial, Trial of the century, HPV16, KOL, Food, Safety, Cancer, Risk, Vaccine, UCI race classifications, PDS, Clinical professor, Therapy, Merck, Mayo Clinic, UNC Lineberger Comprehensive Cancer Center, ASCO, RECIST, Pembrolizumab, Infection, Patient, Immunotherapy, Communication, Nature, PDSB, Journal, National Cancer Institute, Survival, NCI, HNSCC, University of Texas at Austin, Pharmaceutical industry, Thorax, Medicine

VERSATILE-002 is investigating two patient populations of HPV16-positive head and neck cancer patients whose cancer has returned or spread.

Key Points: 
  • VERSATILE-002 is investigating two patient populations of HPV16-positive head and neck cancer patients whose cancer has returned or spread.
  • The first group has not been previously treated with a checkpoint inhibitor (CPI naïve).
  • The second group of patients has failed treatments including checkpoint inhibitor therapy (CPI refractory).
  • Currently, there are no approved therapies for CPI refractory head and neck cancer, with patients typically surviving less than a year.

Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid

Retrieved on: 
일요일, 12월 11, 2022
UNC Lineberger Comprehensive Cancer Center, Annual report, Patient, CAR, Security (finance), Poster, Safety, UNC, Toxic shock syndrome, ASH, B-ALL, Form 10-K, RIM, Society, Cancer, University, COVID-19, Pharmaceutical industry, Vaccine

The presentation, scheduled for today at 6 p.m. CT, will provide data on four patients who received rimiducid to activate the CaspaCIDe® safety switch in an investigator sponsored trial.

Key Points: 
  • The presentation, scheduled for today at 6 p.m. CT, will provide data on four patients who received rimiducid to activate the CaspaCIDe® safety switch in an investigator sponsored trial.
  • The UNC Lineberger research team concluded that iC9 holds promise as a tool to potentially abrogate the most severe CAR T-cell toxicities.
  • Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release.
  • Bellicum assumes no obligation to update Bellicum’s forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

SimBioSys® highlights key advances for medical and surgical planning in breast cancer at SABCS 2022

Retrieved on: 
화요일, 12월 6, 2022
Science, Biotechnology, Research, Surgery, Oncology, General Health, Health, Health Technology, University of North Carolina, Chain reaction, University of Cincinnati, University of Chicago, Research, Biomarker, Patient, Cancer, Breast cancer, Disease, Artificial intelligence, UNC Lineberger Comprehensive Cancer Center, University, Medical imaging, Pharmaceutical industry, Simbiosys

SimBioSys, the precision oncology company behind the 4D Tumor Modelingtechnology, is presenting their latest breast cancer research and introducing new technology applications at the 2022 San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • SimBioSys, the precision oncology company behind the 4D Tumor Modelingtechnology, is presenting their latest breast cancer research and introducing new technology applications at the 2022 San Antonio Breast Cancer Symposium (SABCS).
  • The studies covering six separate poster presentations at SABCS are based on data from both internal and external validation studies of SimBioSys proprietary platform.
  • The results include collaborations with top cancer research institutions, multi-institutional analysis, enhanced visualization, and volumetric prediction capabilities to aid surgical planning as well as novel biomarkers.
  • We are incredibly proud of the research and clinical collaborations with key leaders in breast cancer and the impact our technology can have in breast cancer care, said Dr. Anuja Antony, Chief Medical Officer of SimBioSys.

University of North Carolina's Tylee Craft Selected for 2022 Disney Spirit Award

Retrieved on: 
수요일, 11월 30, 2022
UNC, University of North Carolina, University, Tar Heel, Patient, UNC Lineberger Comprehensive Cancer Center, Courage, Walt Disney World, Disney Sports Enterprises, Disney's Wide World of Sports Spirit Award, Disease, Lung cancer, ESPN College Basketball, White ribbon, Cancer, Family, Boston College, University of North Carolina at Chapel Hill, Immunotherapy, Film, Craft

LAKE BUENA VISTA, Fla., Nov. 30, 2022 /PRNewswire/ -- University of North Carolina wide receiver Tylee Craft has been named the recipient of the 2022 Disney Spirit Award just eight months after nearly losing his life to lung cancer.

Key Points: 
  • LAKE BUENA VISTA, Fla., Nov. 30, 2022 /PRNewswire/ -- University of North Carolina wide receiver Tylee Craft has been named the recipient of the 2022 Disney Spirit Award just eight months after nearly losing his life to lung cancer.
  • "The Disney Spirit Award honors people like Tylee who focus on helping others even while facing their own tremendous adversity."
  • Kelley will present Craft with the Disney Spirit Award during the Home Depot College Football Awards December 8, 2022.
  • Craft is the 27th recipient of the Disney Spirit Award and the first from the University of North Carolina.

First Citizens Bank’s 2022 Holiday Campaign Celebrates Teen Cancer America’s 10th Anniversary

Retrieved on: 
화요일, 11월 29, 2022
Vanderbilt, Adolescence, Credit card, Citizenship, National Cancer Institute, Cancer, Hospital, Social media, Physician, Bank, Patient, Associate, UNC Lineberger Comprehensive Cancer Center, TCA, First Citizens BancShares, Thought, Holiday, First Citizens Bank (Trinidad and Tobago), Health, National Cancer Registrars Association, Hope, Toy, Birth control, Health insurance

RALEIGH, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) -- To honor Teen Cancer Americas (TCA) 10th anniversary of helping teens and young adults with cancer, First Citizens Bank is encouraging everyone to make a donation to the nonprofit this holiday season.

Key Points: 
  • RALEIGH, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) -- To honor Teen Cancer Americas (TCA) 10th anniversary of helping teens and young adults with cancer, First Citizens Bank is encouraging everyone to make a donation to the nonprofit this holiday season.
  • The banks holiday campaign for TCA runs through Dec. 31, 2022.
  • Teen Cancer America has made tremendous strides in improving health and wellness programs for teens and young adults with cancer, as well as medical outcomes.
  • In addition to customers, families and associates, Im inviting everyone to join with First Citizens this holiday season in supporting this worthwhile cause.

Carrie Tompkins Stricker, PhD, RN, ANP-BC, CRNP, Receives APSHO Award for Excellence in Oncology Advanced Practice

Retrieved on: 
수요일, 11월 9, 2022
Aurora, Andrés Carevic, Health, MSN, AP, MD, NCI, Letter, City, University, CT, Hematology, Practitioner, Journal, FNP, FAAN, Pancreatic cancer, RN, Senate, Learning, LLC, DNP, Education, APRN, Doctor of Philosophy, UNC Lineberger Comprehensive Cancer Center, AOCN, Duke Cancer Institute, AbbVie, Leadership, AOCNP, ANP, Research, Pharmacist, Hartford Hospital, Medicine

LAWRENCEVILLE, N.J., Nov. 9, 2022 /PRNewswire-PRWeb/ -- The Advanced Practitioner Society for Hematology and Oncology (APSHO) presented the fifth annual Mary Pazdur Award for Excellence in Advanced Practice in Oncology to Carrie Tompkins Stricker, PhD, RN, ANP-BC, CRNP, an associate professor at Thomas Jefferson University College of Nursing. Created in honor of the late Mary Pazdur, RN, MSN, the award is presented to an advanced practitioner and member of APSHO who consistently demonstrates exemplary leadership and outstanding contributions to clinical practice, research, and education in the oncology/hematology field.

Key Points: 
  • The award recognizes an exceptional leader, mentor, and champion of advanced practice in oncology/hematology.
  • LAWRENCEVILLE, N.J., Nov. 9, 2022 /PRNewswire-PRWeb/ -- The Advanced Practitioner Society for Hematology and Oncology (APSHO) presented the fifth annual Mary Pazdur Award for Excellence in Advanced Practice in Oncology to Carrie Tompkins Stricker, PhD, RN, ANP-BC, CRNP, an associate professor at Thomas Jefferson University College of Nursing.
  • The award ceremony took place during JADPRO Live, an annual educational event during which the APSHO annual meeting takes place.
  • The Advanced Practitioner Society for Hematology and Oncology (APSHO) is a society of nearly 4,000 oncology advanced practitioners, including nurse practitioners, physician assistants, pharmacists, clinical nurse specialists, and other health-care professionals.

Michael Aldridge, Seasoned Biotech Executive, Appointed CEO of Focal Medical

Retrieved on: 
화요일, 11월 1, 2022
Biotechnology, Medical Devices, Health, Pharmaceutical, Oncology, UNC School of Medicine, Toxicity, Growth, Pancreatic cancer, CEO, Translational medicine, Stanford University, FOLFIRINOX, Clinical trial, Research, IND, Khosla Ventures, Brunei Research Department (International), UNC Lineberger Comprehensive Cancer Center, Mallinckrodt, COO, Patent, Incidence, Sanjiv Sam Gambhir, Massachusetts Institute of Technology, Survival rate, University, Chemical engineering, Company, Neoplasm, FDA, Patient, Multimedia, Therapy, Diagnosis, 3D printing, Pharmaceutical industry, Medical imaging, Pharmacology, Technology, Medicine

Michael joins Focal Medical with more than 25 years of experience in the biopharma industry.

Key Points: 
  • Michael joins Focal Medical with more than 25 years of experience in the biopharma industry.
  • View the full release here: https://www.businesswire.com/news/home/20221101006248/en/
    Focal Medical appoints Michael Aldridge CEO (Photo: Business Wire)
    Focal Medical is the new name of Advanced Chemotherapy Technologies.
  • Focal Medicals corporate rebranding is a function of a strategic shift towards broader product applications of its targeted drug delivery technology.
  • To date, Focal Medical has raised over $20 million in equity and grant funding.

PDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable

Retrieved on: 
목요일, 10월 27, 2022
University, Clinical research, Cancer, Goal, Pharynx, Clinical professor, PDS, PDSB, Merck & Co., Nature, Thorax, MD Anderson Cancer Center, Incidence, NCI, Survival, Trial of the century, Nasdaq, Environment, Merck, Department, Communication, Biotechnology, Patient, Infection, Research, Review, Twitter, Investor relations, ET, Partnership, Company, MD, National Cancer Institute, Disease, Recurrence, Immunotherapy, UNC School of Medicine, DRS, Sharp, Cervical cancer, GLOBE, University of Texas at Austin, Mayo Clinic, Risk, Therapy, SEC, Clinical trial, Forward-looking statement, Vaccine, Neoplasm, National, Quality of life, KOL, COVID-19, UNC Lineberger Comprehensive Cancer Center, Caregiver, Pharmaceutical industry, Head, Medicine

FLORHAM PARK, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today provided highlights from its Head and Neck Cancer Key Opinion Leader (KOL) Roundtable. The virtual event was held from 8:30 to 9:30 AM, ET on Wednesday, October 26, 2022.  

Key Points: 
  • FLORHAM PARK, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today provided highlights from its Head and Neck Cancer Key Opinion Leader (KOL) Roundtable.
  • The Head and Neck Cancer KOL Roundtable was moderated by PDS Biotechs Chief Medical Officer, Lauren V. Wood, MD, and featured presentations from Neil D. Gross, MD, Director of Clinical Research and Head of the Oropharynx Section in the Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center; Katharine A.
  • Price, MD, Co-chair, Head, and Neck Disease Group, Mayo Clinic; and Jared Weiss, MD, Section Chief, Thoracic and Head/Neck Oncology, Lineberger Comprehensive Cancer Center, UNC School of Medicine.
  • We are very honored to have had the opportunity to conduct a KOL Roundtable featuring such an accomplished panel of experts in head and neck cancer research and treatment, said Dr. Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotech.